SEC Company Response from Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Feb 6, 2019
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: Feb. 6, 2019 · CIK: 0001711786 · Accession: 0001615774-19-002003
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227772
Letter
Re: Hoth Therapeutics, Inc.
February 6, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1 (File No. 333-227772)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Laidlaw & Company (UK) Ltd. (“Laidlaw”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Hoth Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter, on February 11, 2019, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”). Laidlaw affirms that it is aware of its obligations under the Act in connection with this offering.
Pursuant to Rule 460 under the Act, please be advised that during the period from January 11, 2019 through the date of this letter, copies of the preliminary prospectus, dated January 11, 2019 (the “Preliminary Prospectus”), in connection with the registration statement were distributed (either in print or electronic form) approximately as follows:
Copies to prospective underwriters and dealers:
Copies to prospective institutional investors:
Copies to prospective retail investors:
Total:
Copies of the Preliminary Prospectus were available to anyone requesting the same at the offices of the underwriters.
The Representative confirms on behalf of itself and the several underwriters that they have complied with and will continue to comply with Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Sincerely,
Laidlaw &
Company (UK) Ltd.
Show Raw Text
CORRESP
1
filename1.htm
February 6, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549
Re: Hoth Therapeutics, Inc.
Registration Statement on Form S-1
(File No. 333-227772)
Concurrence in Acceleration Request
Ladies and Gentlemen:
Laidlaw &
Company (UK) Ltd. (“Laidlaw”), as representative of the underwriters for the referenced offering, hereby concurs
in the request by Hoth Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated
to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter, on February 11, 2019, pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”). Laidlaw affirms that it is aware of its obligations under the Act in connection
with this offering.
Pursuant to Rule
460 under the Act, please be advised that during the period from January 11, 2019 through the date of this letter, copies of the
preliminary prospectus, dated January 11, 2019 (the “Preliminary Prospectus”), in connection with the registration
statement were distributed (either in print or electronic form) approximately as follows:
Copies to prospective underwriters and dealers:
0
Copies to prospective institutional investors:
20
Copies to prospective retail investors:
100
Total:
120
Copies of the Preliminary Prospectus
were available to anyone requesting the same at the offices of the underwriters.
The Representative confirms on behalf
of itself and the several underwriters that they have complied with and will continue to comply with Rule 15c2-8 promulgated under
the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Sincerely,
Laidlaw &
Company (UK) Ltd.
By:
/s/ Hugh Regan
Name: Hugh Regan
Title: Executive Director